Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOBILE trial of prolonged-release fampridine in multiple sclerosis
NL-OMON37170Phase 2Active, not recruiting
- Sponsor
- Biogen
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dalfampridine in multiple sclerosis (MS), sponsored by Biogen. Primary endpoints: Change from baseline in self-assessed walking disability, Change from baseline in balance by Berg Balance Scale and 9 more. Started Nov 2012; status: active, not recruiting.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON37170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37170.